Search research articles
Contact Us
Filters
Showing results (221-230 of 327) with videos related to
Page
of 33
Sort By:
Cancer
|
August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanoma
Alexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Journal of the American College of Cardiology
|
March 24, 2018
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S Mahmood, Michael G Fradley, Justine V Cohen, et al.
Nature Communications
|
April 7, 2022
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming
Zhaowei Chu, Lei Gu, Yeguang Hu, et al.
Nature Communications
|
January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B Johnson, Monica V Estrada, Roberto Salgado, et al.
Molecular Cancer Therapeutics
|
October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma
David J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
The Oncologist
|
May 30, 2013
Ipilimumab for patients with advanced mucosal melanoma
Michael A Postow, Jason J Luke, Mark J Bluth, et al.
Molecular Cancer Therapeutics
|
October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Nature Communications
|
August 27, 2024
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial
Meghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2026
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma
George Ansstas, Karam Khaddour, Sumedha Sudhaman, et al.
Page
of 33
Search research articles
Search
Showing results (221-230 of 327) with videos related to
Sort By:
Page
of 33
Cancer
|
August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanoma
Alexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Journal of the American College of Cardiology
|
March 24, 2018
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S Mahmood, Michael G Fradley, Justine V Cohen, et al.
Nature Communications
|
April 7, 2022
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming
Zhaowei Chu, Lei Gu, Yeguang Hu, et al.
Nature Communications
|
January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B Johnson, Monica V Estrada, Roberto Salgado, et al.
Molecular Cancer Therapeutics
|
October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma
David J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
The Oncologist
|
May 30, 2013
Ipilimumab for patients with advanced mucosal melanoma
Michael A Postow, Jason J Luke, Mark J Bluth, et al.
Molecular Cancer Therapeutics
|
October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Nature Communications
|
August 27, 2024
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial
Meghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2026
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma
George Ansstas, Karam Khaddour, Sumedha Sudhaman, et al.
Page
of 33